Compare Gilead Sciences, Inc. (GILD) vs Innovative Industrial Properties Inc (IIPR) Price & Performance

Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.

Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.

IIPR trades at $51.87, up 1.25% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Valuation ratios appear attractive with a P/E of 11.75 and P/B of 0.83, while the company maintains a high net income margin of 52.27%. Recent news highlights a $245 million mezzanine loan commitment and a declared $1.90 dividend.

The outlook is cautious due to declining revenue and negative net cash flow in 2025, offset by strong profitability and a discounted valuation. Risks include tenant defaults and dividend sustainability concerns, but analyst consensus suggests upside with a $84.67 price target. The stock presents a high-yield opportunity with significant re-rating potential if operational challenges are managed.